SCHEMBL19652109

SCHEMBL19652109

CN(C(=O)C(C)(C)C)C1CCN(c2ccncn2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.55
TAF1 P21675 1/20 0.47
CECR2 Q9BXF3 1/20 0.47
BRD9 Q9H8M2 1/20 0.47
RIPK1 Q13546 1/20 0.43
AAK1 Q2M2I8 1/20 0.42
CCNC P24863 1/20 0.42
CDK8 P49336 1/20 0.42
LSS P48449 1/20 0.41
SORD Q00796 1/20 0.40
CYP2D6 P10635 1/20 0.40
DPP4 P27487 1/20 0.40
KCNH2 Q12809 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP9 Q86TI2 1/20 0.40
GRM1 Q13255 1/20 0.39
CYP46A1 Q9Y6A2 1/20 0.38
HRH4 Q9H3N8 2/20 0.37
HRH3 Q9Y5N1 2/20 0.37
AKT1 P31749 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL785732 0.86 GPR119 (0.52) GPR119TAF1CECR2BRD9RIPK1
SCHEMBL19658736 0.86 GPR119 (0.52) GPR119TAF1CECR2BRD9RIPK1
SCHEMBL803847 0.84 GPR119 (0.64) GPR119TAF1CECR2BRD9RIPK1
SCHEMBL19652208 0.82 TAF1 (0.49) GPR119TAF1CECR2BRD9RIPK1
SCHEMBL19652105 0.81 KDM4E (0.54) GPR119
SCHEMBL19652289 0.80 GPR119 (0.44) GPR119TAF1CECR2BRD9RIPK1
SCHEMBL19652198 0.78 GPR119 (0.59) GPR119RIPK1AAK1HRH4HRH3
SCHEMBL19652108 0.78 TRPV1 (0.46) GPR119RIPK1AAK1DPP4DPP8
SCHEMBL19652213 0.77 CYP2C19 (0.49) GPR119TAF1CECR2BRD9RIPK1
SCHEMBL19652218 0.77 HRH4 (0.39) GPR119TAF1CECR2BRD9AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10258603-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-04-16 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10258603-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRD3 GPR119 988/4885TAF1 439/4885CECR2 184/4885
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRD3 GPR119 988/4885TAF1 439/4885CECR2 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.